[
    [
        {
            "time": "",
            "original_text": "董秘解码：国脉科技正式从事临床细胞分子遗传医学检验服务",
            "features": {
                "keywords": [
                    "国脉科技",
                    "临床",
                    "细胞分子",
                    "遗传医学",
                    "检验服务"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "董秘解码：国脉科技正式从事临床细胞分子遗传医学检验服务",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[增持评级] 昭衍新药(603127)简评：业绩维持高速增长 订单及产能带动增量",
            "features": {
                "keywords": [
                    "昭衍新药",
                    "增持评级",
                    "业绩",
                    "高速增长",
                    "订单",
                    "产能"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "研发服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级] 昭衍新药(603127)简评：业绩维持高速增长 订单及产能带动增量",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]